Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialGARON, Edward B; CIULEANU, Tudor-Eliade; CZYZEWICZ, Grzegorz et al.Lancet (British edition). 2014, Vol 384, Num 9944, pp 665-673, issn 0140-6736, 9 p.Article

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non―Small-Cell Lung Cancer: A Phase III TrialSCAGLIOTTI, Giorgio V; KRZAKOWSKI, Maciej; PAPAI, Zsolt S et al.Journal of clinical oncology. 2012, Vol 30, Num 17, pp 2070-2078, issn 0732-183X, 9 p.Article

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non―Small-Cell Lung Cancer: Final Results of a Phase III TrialSOCINSKI, Mark A; BONDARENKO, Igor; IGLESIAS, Jose L et al.Journal of clinical oncology. 2012, Vol 30, Num 17, pp 2055-2062, issn 0732-183X, 8 p.Article

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung CancerSOCINSKI, Mark A; SMIT, Egbert F; JASSEM, Jacek et al.Journal of clinical oncology. 2009, Vol 27, Num 28, pp 4787-4792, issn 0732-183X, 6 p.Article